合并2型糖尿病与肥胖的商业保险人群自付费用:Ozempic与袖状胃切除术的比较
在雇主保险回顾性理赔数据库中,将2017至2021年间接受袖状胃切除术或持续使用Ozempic至少2年的2型糖尿病合并肥胖成人按1:1倾向性匹配后比较自付费用。治疗后1年两组自付医疗费用相似,2年时袖状胃切除术组自付费用显著低于Ozempic组。
要点
- 匹配后袖状胃切除术组与Ozempic组各302例,平均年龄50岁,基线平均BMI 40,男性占41%。
- 治疗后1年自付医疗费用两组相似:袖状胃切除术组2267美元 vs Ozempic组2131美元(差值136美元,P=0.19)。
- 治疗后2年袖状胃切除术组自付医疗费用显著低于Ozempic组(1155美元 vs 2084美元,P<0.01)。
核心结论
- 开始治疗后2年内,接受袖状胃切除术者的自付医疗费用显著低于使用Ozempic者。
研究设计与样本
- 雇主保险回顾性理赔数据库Merative™(原Truven IBM Marketscan)2017至2021年数据。
- 纳入BMI 35 kg/m2或更高且患2型糖尿病的成人,袖状胃切除术组为接受袖状胃切除术且未开具Ozempic处方者,Ozempic组为持续开具Ozempic处方至少2年且未接受减重手术者。
- 两组按人口学特征、肥胖相关合并症及治疗前一年基线自付费用进行1:1倾向性匹配,每组302例。
- 治疗后两年自付费用采用配对t检验比较。
主要发现
- 匹配队列平均年龄50岁,平均基线BMI 40,男性占41%。
- 治疗后1年自付医疗费用袖状胃切除术组2267美元 vs Ozempic组2131美元(差值136美元,P=0.19)。
- 治疗后2年自付医疗费用袖状胃切除术组1155美元 vs Ozempic组2084美元(P<0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Determine out-of-pocket (OOP) costs two years after sleeve gastrectomy (SG) or initiating Ozempic for patients with type 2 diabetes (T2D) and obesity. SUMMARY BACKGROUND DATA: Individuals with obesity and T2D have a variety of treatment options. Risks and benefits of these treatment options are becoming more well documented; however, the real-world patient costs of these options are not known. METHODS: Adults with body mass index (BMI) 35 kg/m2 or higher, and T2D who had an SG or used Ozempic were identified in the employer-based retrospective claims database Merative™ (previously Truven IBM Marketscan) from 2017 to 2021. SG cohort was defined as having a SG (without filling a prescription for Ozempic) and Ozempic cohort was defined as continuously filling a prescription for Ozempic for at least 2 years (and not having any bariatric surgery). Individuals in each cohort were 1:1 propensity matched on demographics, obesity-related comorbidities, and baseline OOP costs. in the year before treatment. OOP costs were compared in the two years after treatment using paired t-tests. RESULTS: 302 SG were matched to 302 Ozempic patients (mean age 50, mean baseline BMI 40, 41% male). OOP healthcare costs were similar for the SG ($2,267) and Ozempic ($2,131) cohorts 1-year after index date (difference=$136, P=0.19). OOP healthcare costs were significantly lower in the SG cohort ($1,155 vs. $2,084, P<0.01) 2-years after index date. CONCLUSIONS: Within 2 years of starting treatment, OOP healthcare costs were significantly lower among individuals who had a SG versus those treated with Ozempic.
引用
- Edwards MA, Wall-Wieler E, Liu Y, et al. Out-of-Pocket Costs among Commercially Insured Individuals with type 2 Diabetes and Obesity: Comparison between Ozempic and Sleeve Gastrectomy. Ann Surg. 2024. PMID: 38775477. doi:10.1097/SLA.0000000000006353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。